Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and : Significant Insider Selling in Shares of Eli Lilly (LLY) Continues

06/11/2021 | 10:22pm EDT


ę MT Newswires 2021
All news about ELI LILLY AND COMPANY
03:01pELI LILLY AND : Lilly releases donanemab data that demonstrated relationship bet..
PR
10:57aELI LILLY AND : Incyte Get Expanded Emergency Use Approval for Baricitinib as Mo..
MT
10:02aEli Lilly, Kumquat Biosciences Form Cancer Collaboration
DJ
09:27aELI LILLY AND : FDA broadens existing emergency use of Lilly and Incyte's barici..
PR
09:03aELI LILLY AND : Unit, Kumquat Biosciences to Develop Molecules for Tumor Immunit..
MT
08:04aLilly, Incyte Get Emergency Use Authorization for Covid-19 Treatment as Monot..
DJ
07:49aELI LILLY AND : Unit, Kumquat Biosciences to Develop Molecules to Invoke Tumor I..
MT
06:46aELI LILLY AND : Lilly and Kumquat Biosciences Announce Collaboration to Discover..
PR
07/23ELI LILLY AND : (LLY) sees Significant Insider Selling Continuing
MT
07/23A Guiding Light For The Research Safe Harbor And "Research Tools"?
AQ
More news
Financials (USD)
Sales 2021 27 265 M - -
Net income 2021 6 579 M - -
Net Debt 2021 11 244 M - -
P/E ratio 2021 34,0x
Yield 2021 1,33%
Capitalization 224 B 224 B -
EV / Sales 2021 8,63x
EV / Sales 2022 8,36x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 246,51 $
Average target price 241,90 $
Spread / Average Target -1,87%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY46.00%224 084
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%332 374
PFIZER, INC.18.04%243 220
NOVARTIS AG0.39%223 750
ABBVIE INC.10.64%209 386